Black Box Warning: Is Ketorolac Safe for Use After Cardiac Surgery?

  • Lisa Oliveri
    Affiliations
    Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, Florida

    Lynn Heart and Vascular Institute, Boca Raton Regional Hospital, Boca Raton, Florida
    Search for articles by this author
  • Katie Jerzewski
    Affiliations
    Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, Florida

    Lynn Heart and Vascular Institute, Boca Raton Regional Hospital, Boca Raton, Florida
    Search for articles by this author
  • Alexander Kulik
    Correspondence
    Address reprint requests to Alexander Kulik, Lynn Heart and Vascular Institute, Boca Raton Regional Hospital, 801 Meadows Road, Suite 104, Boca Raton, Florida, 33486.
    Affiliations
    Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, Florida

    Lynn Heart and Vascular Institute, Boca Raton Regional Hospital, Boca Raton, Florida
    Search for articles by this author
Published:November 13, 2013DOI:https://doi.org/10.1053/j.jvca.2013.07.014

      Objective

      In 2005, after the identification of cardiovascular safety concerns with the use of nonsteroidal anti-inflammatory drugs (NSAIDs), the FDA issued a black box warning recommending against the use of NSAIDs following cardiac surgery. The goal of this study was to assess the postoperative safety of ketorolac, an intravenously administered NSAID, after cardiac surgery.

      Design

      Retrospective observational study.

      Setting

      Single center, regional hospital.

      Participants

      A total of 1,309 cardiac surgical patients (78.1% coronary bypass, 28.0% valve) treated between 2006 and 2012.

      Interventions

      A total of 488 of these patients received ketorolac for postoperative analgesia within 72 hours of surgery.

      Measurement and Main Results

      Ketorolac-treated patients were younger, had better preoperative renal function, and underwent less complex operations compared with non-ketorolac patients. Ketorolac was administered, on average, 8.7 hours after surgery (mean doses: 3.1). Postoperative outcomes for ketorolac-treated patients were similar to those expected using Society of Thoracic Surgery database risk-adjusted outcomes. In unadjusted analysis, patients who received ketorolac had similar or better postoperative outcomes compared with patients who did not receive ketorolac, including gastrointestinal bleeding (1.2% v 1.3%; p = 1.0), renal failure requiring dialysis (0.4% v 3.0%; p = 0.001), perioperative myocardial infarction (1.0% v 0.6%; p = 0.51), stroke or transient ischemic attack (1.0% v 1.7%; p = 0.47), and death (0.4% v 5.8%; p<0.0001). With adjustment in a multivariate model, treatment with ketorolac was not a predictor for adverse outcome in this cohort (odds ratio: 0.72; p = 0.23).

      Conclusions

      Ketorolac appears to be well-tolerated for use when administered selectively after cardiac surgery. Although a black box warning exists, the data highlights the need for further research regarding its perioperative administration.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Cardiothoracic and Vascular Anesthesia
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Brennan F.
        • Carr D.B.
        • Cousins M.
        Pain management: A fundamental human right.
        Anesth Analg. 2007; 105: 205-221
        • Bainbridge D.
        • Cheng D.C.
        • Martin J.E.
        • et al.
        NSAID-analgesia, pain control and morbidity in cardiothoracic surgery.
        Can J Anaesth. 2006; 53: 46-59
        • Kulik A.
        • Ruel M.
        • Bourke M.E.
        • et al.
        Postoperative naproxen after coronary artery bypass surgery: A double-blind randomized controlled trial.
        Eur J Cardiothorac Surg. 2004; 26: 694-700
        • Lin J.C.
        • Szwerc M.F.
        • Magovern J.A.
        Non-steroidal anti-inflammatory drug-based pain control for minimally invasive direct coronary artery bypass surgery.
        Heart Surg Forum. 1999; 2: 169-171
        • Hynninen M.S.
        • Cheng D.C.
        • Hossain I.
        • et al.
        Non-steroidal anti-inflammatory drugs in treatment of postoperative pain after cardiac surgery.
        Can J Anaesth. 2000; 47: 1182-1187
        • Litvak K.M.
        • McEvoy G.K.
        Ketorolac, an injectable nonnarcotic analgesic.
        Clin Pharm. 1990; 9: 921-935
        • Brown C.R.
        • Moodie J.E.
        • Wild V.M.
        • et al.
        Comparison of intravenous ketorolac tromethamine and morphine sulfate in the treatment of postoperative pain.
        Pharmacotherapy. 1990; 10: 116S-121S
        • Stouten E.M.
        • Armbruster S.
        • Houmes R.J.
        • et al.
        Comparison of ketorolac and morphine for postoperative pain after major surgery.
        Acta Anaesthesiol Scand. 1992; 36: 716-721
        • Gillis J.C.
        • Brogden R.N.
        Ketorolac: A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management.
        Drugs. 1997; 53: 139-188
      1. FDA U.S. Food and Drug Administration: Public Health Advisory—FDA announces important changes and additional warnings for COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs) (4 April 2005). Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm150314.htm. Accessed October 19, 2012

        • Ott E.
        • Nussmeier N.A.
        • Duke P.C.
        • et al.
        Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery.
        J Thorac Cardiovasc Surg. 2003; 125: 1481-1492
        • Nussmeier N.A.
        • Whelton A.A.
        • Brown M.T.
        • et al.
        Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.
        N Engl J Med. 2005; 352: 1081-1091
        • Kulkarni S.K.
        • Jain N.K.
        • Singh A.
        Cyclooxygenase isoenzymes and newer therapeutic potential for selective COX-2 inhibitors.
        Methods Find Exp Clin Pharmacol. 2000; 22: 291-298
        • Apfelbaum J.L.
        • Chen C.
        • Mehta S.S.
        • et al.
        Postoperative pain experience: Results from a national survey suggest postoperative pain continues to be undermanaged.
        Anesth Analg. 2003; 97: 534-540
        • White P.F.
        The changing role of non-opioid analgesic techniques in the management of postoperative pain.
        Anesth Analg. 2005; 101: S5-22
        • Fitzgerald G.A.
        Coxibs and cardiovascular disease.
        N Engl J Med. 2004; 351: 1709-1711
        • Ray W.A.
        • Varas-Lorenzo C.
        • Chung C.P.
        • et al.
        Cardiovascular risks of nonsteroidal anti-inflammatory drugs in patients after hospitalization for serious coronary heart disease.
        Circ Cardiovasc Qual Outcomes. 2009; 2: 155-163
        • Trelle S.
        • Reichenbach S.
        • Wandel S.
        • et al.
        Cardiovascular safety of non-steroidal anti-inflammatory drugs: Network meta-analysis.
        BMJ. 2011; 342: c7086
        • Engoren M.C.
        • Habib R.H.
        • Zacharias A.
        • et al.
        Postoperative analgesia with ketorolac is associated with decreased mortality after isolated coronary artery bypass graft surgery in patients already receiving aspirin: A propensity-matched study.
        J Cardiothorac Vasc Anesth. 2007; 21: 820-826
        • Engoren M.
        • Hadaway J.
        • Schwann T.A.
        • et al.
        Ketorolac improves graft patency after coronary artery bypass grafting: A propensity-matched analysis.
        Ann Thorac Surg. 2011; 92: 603-609
        • Knijff-Dutmer E.A.
        • Kalsbeek-Batenburg E.M.
        • Koerts J.
        • et al.
        Platelet function is inhibited by non-selective non-steroidal anti-inflammatory drugs but not by cyclo-oxygenase-2-selective inhibitors in patients with rheumatoid arthritis.
        Rheumatology (Oxford). 2002; 41: 458-461
        • Gupta A.
        • Daggett C.
        • Drant S.
        • et al.
        Prospective randomized trial of ketorolac after congenital heart surgery.
        J Cardiothorac Vasc Anesth. 2004; 18: 454-457
        • Moffett B.S.
        • Wann T.I.
        • Carberry K.E.
        • et al.
        Safety of ketorolac in neonates and infants after cardiac surgery.
        Paediatr Anaesth. 2006; 16: 424-428
        • Lee A.
        • Cooper M.C.
        • Craig J.C.
        • et al.
        Effects of nonsteroidal anti-inflammatory drugs on postoperative renal function in adults with normal renal function.
        Cochrane Database Syst Rev. 2007; 18: CD002765
        • Singh G.
        • Ramey D.R.
        • Morfeld D.
        • et al.
        Comparative toxicity of non-steroidal anti-inflammatory agents.
        Pharmacol Ther. 1994; 62: 175-191
        • Acharya M.
        • Dunning J.
        Does the use of non-steroidal anti-inflammatory drugs after cardiac surgery increase the risk of renal failure?.
        Interact Cardiovasc Thorac Surg. 2010; 11: 461-467
        • Castellsague J.
        • Riera-Guardia N.
        • Calingaert B.
        • et al.
        Individual NSAIDs and upper gastrointestinal complications: A systematic review and meta-analysis of observational studies (the SOS project).
        Drug Saf. 2012; 35: 1127-1146
        • Chang C.H.
        • Shau W.Y.
        • Kuo C.W.
        • et al.
        Increased risk of stroke associated with nonsteroidal anti-inflammatory drugs: A nationwide case-crossover study.
        Stroke. 2010; 41: 1884-1890